Hengrui Pharma Reaches Agreement with GSK, Expected to Receive $12 Billion
View all comments(0)
Hengrui Pharma announced that it has reached an agreement with biopharmaceutical company GSK to grant paid licenses to GSK for the global exclusive rights of the HRS-9821 project (excluding mainland China, Hong Kong SAR, Macau SAR, and Taiwan) and the exclusive option for the global exclusive license of up to 11 projects.
GSK will pay Hengrui $500 million as an initial payment. If all projects are granted exclusive options and all milestones are achieved, Hengrui will be eligible to receive a potential total amount of around $12 billion based on successful development, registration, and sales milestone payments.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
【US Pre-Market】Nasdaq Leads Losses in Three Major Stock Index Futures, IONQ Surges Over 11%, RGTI Rises Over 5% as Market Focuses on US-China Summit

Meta Connect 2026 Preview: Phoenix Headset and AI Glasses Take Center Stage, Can Meta Reshape the XR Ecosystem?

SPCX Stock Price Prediction: SpaceX President Plans to Sell $52 Million of Stock, Can the Stock Keep Rising?

Meta Shares Surge Over 8% to Highest Since February as Connect 2026 Nears, Muse Agent May Become New AI Variable

Micron Shares Hold Steady at $1,000 With Record High in Sight as Citi Sees Rise to $1,300







Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.